Covid-19 updates: Gilead Sciences Inc’s antiviral remdesivir could be priced up to $5,080 per course <br /> <br />The first clinical trial of Covid-19 vaccine developed by the Oxford University has begun in South Africa. <br /> <br />The global fight against Covid-19 pandemic is intensifying with medical experts and drugmakers from across the world ramping up effort to arrive at the potential coronavirus vaccine and treatment. <br /> <br />With nearly 10 million Covid-19 patients across the globe and over 4.8 coronavirus fatalities, the virus has almost the entire planet under its grip and the need for a Covid-19 antidote becomes more urgent by the day. <br /> <br />American biopharmaceutical company Gilead Sciences has said it will soon start clinical trials for an inhaled formulation of its antiviral drug remdesivir used for the treatment of Covid-19. Remdesivir has made great strides in its role in the formulation of a vaccine against the contagion. <br /> <br />Here are the latest development on Covid-19 vaccine and treatment: <br /> <br />
